港股異動 | 優然牧業升6% 核心業務持續雙位數增長
格隆匯4月6日丨優然牧業(9858.HK)升6% ,報2.14港元,總市值81億港元。優然牧業公佈2022年年報,實現收入180.51億元,同比增17.6%,領先優勢持續擴大。四大業務繼續保持雙位數以上增長,行業龍頭地位穩固:原料奶收入同比增13.8%,飼料收入同比增23.4%,奶牛超市收入同比增13.9%,育種收入同比大增120.8%。現金EBITDA 35.91億元,與去年基本持平,管理費用率及銷售費用率分別由5.4%、3.6%下降至4%和3.3%,連續三年下降,大幅低於行業,營運效率持續提升。公司擬分紅每股派息0.022元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.